If you have been reading about peptide acylation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
== Technology overview == In analytical chromatography, the goal is to separate and uniquely identify each of the compounds in a substance. Alternatively, preparative scale chromatography is a method of purification of large batches of material in a production environment. The basic methods of separation in HPLC rely on a mobile phase (water, organic solvents, etc.) being passed through a stationary phase (particulate silica packings, monoliths, etc.) in a closed environment (column); the differences in reactivity among the solvent of interest and the mobile and stationary phases distinguish compounds from one another in a series of adsorption and desorption phenomena. The results are then visually displayed in a resulting chromatogram. Stationary phases are available in many varieties of packing styles as well as chemical structures and can be functionalized for added specificity. Monolithic-style columns, or monoliths, are one of many types of stationary phase structure. Monoliths, in chromatographic terms, are porous rod structures characterized by mesopores and macropores. These pores provide monoliths with high permeability, a large number of channels, and a high surface area available for reactivity. The backbone of a monolithic column is composed of either an organic or inorganic substrate in, and can easily be chemically altered for specific applications. Their unique structure gives them several physico-mechanical properties that enable them to perform competitively against traditionally packed columns.
Narrated by Martin Jarvis 7 August Turbo: Qualifying Boost, Paul Ray and electronic engineer Steve Taylor, who designed the engine management unit, at Cosworth; each year in Formula 1, the permitted fuel was reduced - for 1986, it was 195 litres; the EEC-IV electronic fuel injection system, an EPROM design; the Lola THL2 is tested at Boreham Circuit in Essex on 21 February 1986, with Patrick Tambay; Geoff Goddard, of Cosworth, who designed the overall engine; automotive engineer Neil Oatley; aerodynamicist Ross Brawn at Cranfield Institute of Technology; 4 March 1986 at Donington Park in Leicestershire; the Haas Lola team, and Cosworth development engineer Martin Walters; the Lotus 98T, of Team Lotus, with its Renault engine; the wastegate of a turbocharger compressor; the 1986 San Marino Grand Prix in northern Italy on 27 April 1986; the Chernobyl disaster had taken place the day before; Paul Ray notices that the exhaust has cracked near the turbocharger; Narrated by Martin Jarvis, produced by Patrick Uden, made by Uden Associates 14 August Prisoner of Consciousness, Sir Jonathan Miller looked at his research into human memory, and 48-year-old BBC musician Clive Wearing, who could not remember more than 10 seconds; Miller had made The Body in Question for the BBC in 1978, with much of the future Equinox team. Directed by John Dollar, produced by Patrick Uden, and made by Uden Associates 21 August A Short History of the Future: The City.
=== Music === Mass (band), an English post-punk band Mass (music), a choral composition that sets liturgical text to music Mass (Stravinsky), a composition by Igor Stravinsky Mass (Bernstein), a musical theater work by Leonard Bernstein Mass (Grotus album), 1996 Mass (The Gazette album), 2021 The Mass (album), by musical project Era Mass, a 2011 album by New Zealand musician Alastair Galbraith
Alice in Chains has sold over 30 million certified records in the United States, released two number-one albums, had 23 top 40 singles, and has received eleven Grammy Award nominations. The band was ranked number 34 on VH1's 100 Greatest Artists of Hard Rock. Alice in Chains was named 15th greatest live band by Hit Parader, with Staley placing as 27th-greatest heavy metal vocalist of all time. The band's second album, Dirt, was named 5th-best album in the last two decades by Close-Up magazine in 2008. In October 2008, Guitar World ranked Cantrell's solo in "Man in the Box" at No. 77 on their list of "100 Greatest Guitar Solos". In August 2009, Alice in Chains won the Kerrang! Icon Award. In November 2011, Jar of Flies was ranked number four on Guitar World magazine's top ten list of guitar albums of 1994. It was also featured in Guitar World magazine's "Superunknown: 50 Iconic Albums That Defined 1994" list, and in May 2014, the EP was placed at number five on Loudwire's "10 Best Hard Rock Albums of 1994" list. In June 2017, Metal Injection ranked Alice in Chains at number 1 on their list of "10 Heaviest Grunge Bands". Ozzy Osbourne ranked Facelift among his list of "10 Favorite Metal Albums".
On January 4, 2008, the results of a mitochondrial DNA test, comparing the child's DNA with that of his potential grandmother, Clara de Rojas, were revealed by the Colombian government. It was reported that there was a very high probability that the boy was indeed part of the Rojas family. The same day, FARC released a communique in which they admitted that Emmanuel had been taken to Bogotá and "left in the care of honest persons" for safety reasons until a humanitarian exchange took place. The group accused President Uribe of "kidnapping" the child to sabotage his liberation. However, on January 10, 2008, FARC released Rojas and Gonzalez through a humanitarian commission headed by the International Committee of the Red Cross. On January 13, 2008, Venezuelan President Hugo Chávez stated his disapproval with the FARC strategy of armed struggle and kidnapping saying, "I don't agree with kidnapping and I don't agree with armed struggle". He repeated his call for a political solution and an end to the war in March and June 2008: "The guerrilla war is history...At this moment in Latin America, an armed guerrilla movement is out of place". In February 2008, FARC released four other political hostages "as a gesture of goodwill" toward Chávez, who had brokered the deal and sent Venezuelan helicopters with Red Cross logos into the Colombian jungle to pick up the freed hostages. On March 1, 2008, the Colombian armed forces launched a military operation 1.8 kilometres into Ecuador on a FARC position, killing 24, including Raúl Reyes, member of the FARC Central High Command.
Sources: en.wikipedia.org
Sex pheromones are probably important in earthworms because they live in a concealed subterranean environment where chemical signalling may play a crucial role in attracting a partner and in facilitating outcrossing. Outcrossing would provide the benefit of masking the expression of deleterious recessive mutations in progeny. (see Complementation). Copulation and reproduction are separate processes in earthworms. The mating pair overlap front ends ventrally and each exchanges sperm with the other. The clitellum becomes very reddish to pinkish in colour. Sometime after copulation, long after the worms have separated, the clitellum (behind the spermathecae) secretes material which forms a ring around the worm. The worm then backs out of the ring, and as it does so, it injects its own eggs and the other worm's sperm into it. Thus each worm becomes the genetic father of some of their offspring (due to its own sperm transferred to other earthworm) and the genetic mother (offsprings from its own egg cells) of the rest. As the worm slips out of the ring, the ends of the cocoon seal to form a vaguely onion-shaped incubator (cocoon) in which the embryonic worms develop. Hence fertilization is external. The cocoon is then deposited in the soil. After three weeks, 2 to 20 offspring hatch with an average of four. Development is direct that is without formation of any larva.
The underlying principle of COLD-PCR is that single nucleotide mismatches will slightly alter the melting temperature (Tm) of the double-stranded DNA. Depending on the sequence context and position of the mismatch, Tm changes of 0.2–1.5 °C (0.36–2.7 °F) are common for sequences up to 200bp or higher. Knowing this the authors of the protocol took advantage of two observations:
==== Panama Canal ==== In 2024, Trump demanded that Panama return control of the Panama Canal to the United States because "excessive rates" were being charged for American passage. The United States previously was in control of the Panama Canal Zone from 1903 until 1999, and has invaded Panama before in 1989. Trump told Congress in March 2025 that his administration "will be reclaiming the Panama Canal". Also that month, Defense Secretary Pete Hegseth instructed the Trump administration to "immediately" present "credible military options to ensure fair and unfettered US military and commercial access to the Panama Canal".
Almost exclusively affects women. Starts or worsens at times of hormonal changes: puberty, pregnancy, or menopause. Bilateral, symmetrical buildup of fat in the legs, and sometimes arms and lower trunk, that is resistant to nutritional intervention, exercise, elevation, diuretics, and bariatric surgery. Feet/hands are typically spared, presenting with a raised ridge or fold of fat. In earlier stages, there may be a subtle, raised ridge or fold of fat instead of distinct cuffing to the ankle or wrist. Sometimes, especially in later stages, this increased adipose tissue above the ankle/wrist can cause the appearance of a “cuff” (“pantaloons” is an evocative term sometimes to describe this morphology in later stages). Presence of nodular and/or fibrotic texture beneath the skin, which can create an uneven, dimpled appearance. Complaints of pain, tenderness, and/or heaviness in affected areas. Fatigue, brain fog, easy bruising. Edema and joint hypermobility may also be present. Texture and visual presentation may change with swelling and inflammation.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.